title: Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.
abstract: Our objective is to develop a prophylactic vaccine strategy that can be evaluated for surgical and other high-risk hospitalized patients. In this paper, we describe the preparation and preclinical evaluation of a liposomal complete-core lipopolysaccharide (LPS) vaccine that is nontoxic and broadly antigenic. Complete-core (Ra-chemotype) LPSs were isolated from four gram-negative bacterial strains (Escherichia coli K-12, E. coli R1, Pseudomonas aeruginosa PAC608, and Bacteroides fragilis), mixed together to form a cocktail of complete-core LPSs, and then incorporated into multilamellar liposomes consisting of dimyristoyl phosphatidyl choline, dimyristoyl phosphatidylglycerol, and cholesterol in a 4:1:4 molar ratio. The endotoxic activities of these LPS-containing liposomes were less than 0.1% of the endotoxicities of the original free LPSs as measured by the Limulus amoebocyte lysate assay. In vivo administration of liposomal complete-core LPS mixed with Al(OH)(3) to rabbits resulted in no pyrogenicity or overt toxicity over a 7-day period. In immunoblots, sera from rabbits following active immunization elicited cross-reactive antibodies to a large panel of rough and smooth LPSs from numerous clinically relevant gram-negative bacteria, including E. coli (serotypes O1, O4, O6, O8, O12, O15, O18, O75, O86, O157, and O111), P. aeruginosa (Fisher-Devlin serotypes 1, 2, and 3, which correspond to International Antigenic Typing Scheme types 6, 11, and 2, respectively), Klebsiella pneumoniae (serotypes O1, O2ab, and O3), B. fragilis, and Bacteroides vulgatus. Active immunization of mice with liposomal complete-core LPS provided protection against a lethal challenge with E. coli O18 LPS. The vaccine tested was nontoxic, nonpyrogenic, and immunogenic against a wide variety of pathogens found in clinical settings.
authors.affiliation: Department of Anesthesiology, Columbia University College of Physicians & Surgeons, New York, New York 10032-3784, USA. eb413@columbia.edu
authors.forename: E
authors.initials: E
authors.lastname: Bennett-Guerrero
authors.forename: T J
authors.initials: TJ
authors.lastname: McIntosh
authors.forename: G R
authors.initials: GR
authors.lastname: Barclay
authors.forename: D S
authors.initials: DS
authors.lastname: Snyder
authors.forename: R J
authors.initials: RJ
authors.lastname: Gibbs
authors.forename: M G
authors.initials: MG
authors.lastname: Mythen
authors.forename: I R
authors.initials: IR
authors.lastname: Poxton
mesh_terms: D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000633:toxicity; D005260:Female; D007114:Immunization; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000276:immunology / Q000633:toxicity; D008081:Liposomes; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011817:Rabbits
chemical_list: D001428:Bacterial Vaccines; D008070:Lipopolysaccharides; D008081:Liposomes